Understanding Peptide-Drug Conjugates (PDC) in the Wave of ADCs
In cancer treatment, there are three targeted approaches to enhance the specificity and anti-tumor activity of therapies. Targeted formulations can be designed to inhibit proteins expressed by tumor cells, such as receptors or enzymes; another approach involves binding effector molecules (e.g., ADCs, bispecific antibodies, or CAR-T) to molecules overexpressed on the surface of tumor cells, … Read more